Core Viewpoint - Hongyuan Pharmaceutical has achieved a record trading volume since its listing, indicating strong market interest and investor confidence in the company [2] Group 1: Company Performance - As of 10:42, Hongyuan Pharmaceutical's trading volume reached 1.022 billion yuan, marking a new high since its IPO [2] - The latest stock price increased by 20.00%, with a turnover rate of 25.28% [2] - The previous trading day saw a total trading volume of 825 million yuan [2] Group 2: Company Background - Hubei Hongyuan Pharmaceutical Technology Co., Ltd. was established on January 21, 2002, with a registered capital of 4,000.68 million yuan [2]

Group 1 - The company is currently developing in line with its annual plan expectations [2] - The company has completed the preparation of kilogram-level sulfide electrolyte precursors and electrolyte samples [2] - The company is conducting testing and optimization for solid-state electrolytes and is preparing for pilot line construction [2]

Group 1 - The company confirms that its development in the pharmaceutical sector, particularly in high-end raw materials and formulations, is in line with the annual planning expectations [2] - The company has completed the preparation of kilogram-level sulfide electrolyte precursors and electrolyte samples, and is currently optimizing testing for solid electrolytes while preparing for pilot line construction [2]

Market Overview - The chemical pharmaceutical sector increased by 0.26% on December 25, with Hongyuan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3959.62, up 0.47%, while the Shenzhen Component Index closed at 13531.41, up 0.33% [1] Top Performers - Hongyuan Pharmaceutical (301246) closed at 22.40, up 7.74%, with a trading volume of 392,500 shares and a transaction value of 825 million [1] - Shanghai Yizhong (688091) closed at 48.82, up 4.34%, with a trading volume of 45,600 shares and a transaction value of 220 million [1] - Yiduoli (300381) closed at 6.72, up 3.70%, with a trading volume of 121,500 shares and a transaction value of 80.94 million [1] Underperformers - Tuisu Suwu (600200) closed at 0.31, down 6.06%, with a trading volume of 301,300 shares and a transaction value of 9.64 million [2] - Kangla Pharmaceutical (300086) closed at 12.78, down 3.98%, with a trading volume of 937,200 shares and a transaction value of 1.224 billion [2] - Baile Tianheng (688506) closed at 331.00, down 3.22%, with a trading volume of 10,700 shares and a transaction value of 359 million [2] Capital Flow - The chemical pharmaceutical sector experienced a net outflow of 1.089 billion from institutional investors, while retail investors saw a net inflow of 1.084 billion [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional selling contrasted by retail buying [2] Individual Stock Capital Flow - Hongyuan Pharmaceutical saw a net inflow of 132.15 million from retail investors, while institutional investors had a net outflow of 50.77 million [3] - Shanghai Yizhong had a net inflow of 19.13 million from institutional investors, while retail investors experienced a net outflow of 1.68 million [3] - Yiduoli had a net inflow of 26.80 million from institutional investors, while retail investors had a net outflow of 23.79 million [3]

Market Overview - As of December 24, the Shanghai Composite Index closed at 3940.95 points, up by 20.97 points, representing a 0.53% increase [1] - The Shenzhen Component Index closed at 13486.42 points, up by 117.43 points, with a 0.88% increase [1] - The ChiNext Index closed at 3229.58 points, up by 24.57 points, reflecting a 0.77% increase [1] Stock Performance - A total of 89 A-shares had a turnover rate exceeding 20%, with six stocks, including C Jianxin and C Nabai Chuan, having turnover rates above 50% [1] - C Jianxin (688805) had a closing price of 58.12 yuan and a turnover rate of 77.25%, with a significant increase of 212.81% [1] - C Nabai Chuan (301667) closed at 82.73 yuan, with a turnover rate of 67.98%, but experienced a decline of 28.06% [1] - C Xihua (603248) closed at 26.01 yuan, with a turnover rate of 57.63%, and a decrease of 29.34% [1] - C Tiansu (301449) closed at 75.83 yuan, with a turnover rate of 54.69%, down by 24.93% [1] - Other notable stocks include C Youxun (688807) with a closing price of 231.60 yuan and a turnover rate of 50.23%, up by 14.03% [1] Additional Notable Stocks - Huazhong Cable (001208) closed at 21.05 yuan with a turnover rate of 49.18%, up by 6.10% [1] - Guangdao Tui (920680) closed at 1.32 yuan, with a turnover rate of 46.41%, and an increase of 29.41% [1] - Tongyu Communication (002792) closed at 34.71 yuan, with a turnover rate of 42.86%, up by 6.31% [1] - Shennong Agriculture (300189) closed at 7.90 yuan, with a turnover rate of 41.35%, up by 1.41% [1]

Group 1 - The chemical pharmaceutical sector increased by 0.41% compared to the previous trading day, with Hongyuan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3919.98, up 0.07%, while the Shenzhen Component Index closed at 13368.99, up 0.27% [1] Group 2 - In terms of capital flow, the chemical pharmaceutical sector experienced a net outflow of 777 million yuan from main funds, while retail investors saw a net inflow of 859 million yuan [2] - The net outflow from speculative funds was 81.43 million yuan [2]

宏源药业（301246.SZ）12月23日在投资者互动平台表示，目前公司六氟磷酸钠产品生产和销售正常， 产销均衡。六氟磷酸钠是钠电池的核心原材料，随着六氟磷酸锂市场的好转，六氟磷酸钠价格优势凸 显，未来将更有利于六氟磷酸钠的市场规模扩大。我司现有设计产能400吨/年，后期一旦市场需求发生 较大增长，我司会适时调整增加产能。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：目前六氟磷酸钠产销情况如何？公司如何看待六氟磷 酸钠今后几年的发展，有计划在2026年扩产吗？ ...

Group 1 - The company has completed the preparation of kilogram-level sulfide electrolyte precursors and electrolyte samples [1] - Testing and optimization of solid-state electrolytes are currently underway [1] - The project is being developed in collaboration with Huanggang Normal University [1]

Core Viewpoint - Hongyuan Pharmaceutical (301246.SZ) has successfully completed the preparation of kilogram-level sulfide electrolyte precursors and electrolyte samples, indicating progress in solid electrolyte testing and optimization, and is currently preparing for pilot line construction in collaboration with Huanggang Normal University [1] Group 1 - The company has achieved the preparation of kilogram-level sulfide electrolyte precursors and electrolyte samples [1] - Testing and optimization of solid electrolytes are currently underway [1] - The project is a collaboration with Huanggang Normal University [1]

每经AI快讯，有投资者在投资者互动平台提问：中蓝宏源2024年对公司业绩影响几何？ 宏源药业（301246.SZ）12月15日在投资者互动平台表示，中蓝宏源为公司的参股公司（公司持股 41%），作为长期股权投资，公司对其采用权益法核算，2024年确认投资收益-2,464.15万元。 （文章来源：每日经济新闻） ...